Characteristics of the 155 patients in the CLL cohort
. | Wild type, n = 133 . | ATM mutant, n = 16* . | TP53 mutant, n = 6† . |
|---|---|---|---|
| Male-female (M/F ratio) | 78:55 (1.4) | 8:8 (1.0) | 5:1 (5.0) |
| Median age at diagnosis, y | 66 | 68 | 81.5 |
| Stage at diagnosis | |||
| A | 88 | 11 | 5 |
| B/C | 26 | 4 | 1 |
| Stage at genetic analysis | |||
| A | 66 | 5 | 2 |
| B/C | 60 | 10 | 4 |
| VH gene | (n = 116) | (n = 16) | (n = 6) |
| Unmutated | 29 | 10 | 2 |
| Mutated | 87 | 6 | 4 |
| 11q deletion (n = 77) | (n = 60) | (n = 13) | (n = 4) |
| Present | 5 | 4 | 0 |
| Absent | 55 | 9 | 4 |
| Era of diagnosis | |||
| Before 1996 | 44 | 5 | 0 |
| 1997-2000 | 44 | 6 | 4 |
| 2001-2003 | 45 | 4 | 2 |
| Median follow-up, mo (range) | 68.5 (25-217) | 79 (26-156) | 60.5 (34-88) |
| Percentage treated | 43 | 73 | 66 |
| Median time to treatment, mo (n = 152) | 130 (n = 131) | 40 (n = 15) | 40 (n = 6) |
| Percentage died | 17 | 47 | 66 |
| Median survival, mo (n = 154) | > 217 (n = 133) | 85 (n = 15) | 45 (n = 6) |
. | Wild type, n = 133 . | ATM mutant, n = 16* . | TP53 mutant, n = 6† . |
|---|---|---|---|
| Male-female (M/F ratio) | 78:55 (1.4) | 8:8 (1.0) | 5:1 (5.0) |
| Median age at diagnosis, y | 66 | 68 | 81.5 |
| Stage at diagnosis | |||
| A | 88 | 11 | 5 |
| B/C | 26 | 4 | 1 |
| Stage at genetic analysis | |||
| A | 66 | 5 | 2 |
| B/C | 60 | 10 | 4 |
| VH gene | (n = 116) | (n = 16) | (n = 6) |
| Unmutated | 29 | 10 | 2 |
| Mutated | 87 | 6 | 4 |
| 11q deletion (n = 77) | (n = 60) | (n = 13) | (n = 4) |
| Present | 5 | 4 | 0 |
| Absent | 55 | 9 | 4 |
| Era of diagnosis | |||
| Before 1996 | 44 | 5 | 0 |
| 1997-2000 | 44 | 6 | 4 |
| 2001-2003 | 45 | 4 | 2 |
| Median follow-up, mo (range) | 68.5 (25-217) | 79 (26-156) | 60.5 (34-88) |
| Percentage treated | 43 | 73 | 66 |
| Median time to treatment, mo (n = 152) | 130 (n = 131) | 40 (n = 15) | 40 (n = 6) |
| Percentage died | 17 | 47 | 66 |
| Median survival, mo (n = 154) | > 217 (n = 133) | 85 (n = 15) | 45 (n = 6) |